CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 12 enrolled
Drug / intervention
Wilatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04953884
NCT04953884Phase 3Completed
CompareCT.gov

Clinical Study to Investigate the Efficacy, Pharmacokinetics, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease Patients Under the Age of 6 Years

Octapharma·interventional·Posted Jul 8, 2021·Updated Feb 20, 2026

In Brief

A Phase 3 clinical trial evaluating Wilate for Von Willebrand Disease. Completed, enrolled 12 participants across 9 sites in 7 countries.

Detailed Summary

The WIL-33 study aimed to determine the efficacy, pharmacokinetics, immunogenicity and safety of wilate as routine prophylaxis in up to 12 paediatric patients (eight evaluable) with severe von Willebrand Disease VWD (defined as screening von Willebrand factor ristocetin cofactor activity \[VWF:RCo\] \<20%) under the age of 6 years, over a period of 12 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVon Willebrand Disease
CountriesCzechia, Germany, Moldova, North Macedonia, Russia, Ukraine, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedJul 8, 2021
Enrollment StartSep 22, 2021
Primary CompletionDec 16, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.0 years ago

Interventions

Wilatedrug

Wilate is a plasma-derived, stable, highly purified, double virus inactivated concentrate of freeze-dried active VWF and factor VIII (FVIII) prepared from cryoprecipitate and intended for the treatment of patients with VWD and/or haemophilia A